TiGenix

company

About

TiGenix is a biomedical company focused on research and development of innovative local treatments for damaged and osteoarthritic joints.

  • 101 - 250

Details

Last Funding Type
Private Equity(PE)
Last Funding Money Raised
$7.50M
Industries
Biotechnology,Clinical Trials,Health Care,Medical
Founded date
Jan 1, 2000
Number Of Employee
101 - 250
Operating Status
Active

TiGenix NV (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$21.20M
TiGenix has raised a total of $21.20M in funding over 2 rounds. Their latest funding was raised on Dec 25, 2013 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 25, 2013 Debt Financing $13.70M 1 Detail
Jun 25, 2009 Private Equity(PE) $7.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
TiGenix is funded by 2 investors. Kreos Capital and Limburg Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Kreos Capital Debt Financing
Limburg Ventures Private Equity(PE)